GSK & Sanofi’s Unprecedented COVID-19 Vaccine Collaboration
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
Since it was formed in 1994, the LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare.
The LFB Group is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are medicinal products derived from living organisms in three major fields of therapy: immunology, haemostasis and intensive care.
The LFB group is a biopharmaceutical company, one of the rare manufacturers in the world with expertise in different bioproduction techniques, offering plasma-derived medicinal products, recombinant medicinal products and advanced therapy treatments such as cell therapies. The LFB Group’s strategy is focused on international growth and an active research and development policy in its fields of therapeutic excellence.
LFB is a public company and the Group is growing in a competitive sector, with medicinal products sold in nearly 60 countries.
Over 2000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients.
Every year, LFB’s 23 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
Speaking exclusively to PharmaBoardroom at the International Women’s Day 2020 event at the Franco-British Chamber of Commerce in Paris, esteemed cardiologist Professor Claire Mounier-Vehier outlines why cardiovascular disease is not…
Researchers at the Institut Pasteur in Paris have become the first in Europe to fully sequence the genome of the 2019-nCoV coronavirus – putting the Institut at the forefront of…
These are worrying times for iconic French mid-cap Ipsen. Trials for palovarotene, a treatment for rare bone disorders, have been plagued by setbacks, perhaps contributing to erstwhile CEO David Meek’s…
France is home to the highest rates of vaccine mistrust in Europe, with a third of French people disagreeing that vaccines are safe, according to the Wellcome Global Monitor survey.…
With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing…
France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with top-class institutions, a dense network of…
With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a…
Francois Cornu, president of Eurofins Biomnis, and Gautier Decock, managing director of Eurofins BioPharma Product Testing in France and Belgium, come together to shed light on the company’s unique decentralized…
Nathalie Giraud, director of integrated monitoring investigator services & head of France at PPD, breaks down the strengths and weaknesses of the French clinical trials environment and stresses the importance…
The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain…
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but…
See our Cookie Privacy Policy Here
